
pmid: 18838176
Immune responses to microbial glycolipids that cross-react to neural epitopes may trigger the Guillain-Barré syndrome (GBS). CD1 molecules are involved in antigen presentation of glycolipids and variation in CD1 genes was recently reported to confer susceptibility to develop GBS. This hypothesis was tested by comparing single nucleotide polymorphisms (SNPs) of CD1A and CD1E in 312 well defined GBS patients and 212 healthy controls. SNPs in CD1A and CD1E were not associated with GBS susceptibility, specific clinical subgroups, anti-ganglioside antibodies, antecedent infections and prognosis. Based on this study, CD1 polymorphisms are not a susceptibility or disease modifying factor in GBS.
Adult, Aged, 80 and over, Male, EMC MM-02-72-02, Adolescent, Genotype, EMC MM-04-44-02, Middle Aged, Guillain-Barre Syndrome, Polymorphism, Single Nucleotide, Statistics, Nonparametric, Antigens, CD1, Young Adult, Gene Frequency, Humans, Female, Genetic Predisposition to Disease, Child, Aged
Adult, Aged, 80 and over, Male, EMC MM-02-72-02, Adolescent, Genotype, EMC MM-04-44-02, Middle Aged, Guillain-Barre Syndrome, Polymorphism, Single Nucleotide, Statistics, Nonparametric, Antigens, CD1, Young Adult, Gene Frequency, Humans, Female, Genetic Predisposition to Disease, Child, Aged
| citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 27 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
